ChromaDex Corporation Reports 2017 Financial Results   

IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and full year 2017 financial results.

Results of operations for the three months ended Dec. 30, 2017

For the three months ended Dec. 30, 2017 (“Q4 2017”), ChromaDex reported net sales from continuing operations of $7.5 million, up 69% compared to $4.5 million from continuing operations in the fourth quarter of 2016. The increase in fourth quarter revenues was driven by growth in sales of TRU NIAGEN®.

Gross profit improved in the fourth quarter of 2017 to 50.9% as compared to 45.1% for the same period in 2016. We experienced better margins due to the positive impact of TRU NIAGEN® consumer product sales, which we anticipate will continue.

Operating expenses were $12.6 million in the fourth quarter of 2017, compared to $4.2 million from continuing operations in the same period for 2016. The increase in operating expenses for fourth quarter was the result of our strategic decision to invest in marketing to build out the TRU NIAGEN brand, as well as legal costs associated with ongoing litigation and higher stock-based compensation expense.

The net loss attributable to common stockholders for the fourth quarter of 2017 was $8.8 million or ($0.17) per share as compared to a net loss of $2.1 million or ($0.06) per share for Q4 2016. The higher losses in the fourth quarter were the result of the strategic decision to invest ahead of growth, higher legal fees associated with ongoing litigation and higher stock-based compensation expense, partially offset by higher sales volume and gross profits.

For the fourth quarter of 2017, the reported loss from continuing operations was negatively impacted by a non-cash charge of $3.4 million related to stock-based compensation.

Adjusted EBITDA, a non-GAAP measure, was ($5.2) million for Q4 2017, compared to adjusted EBITDA of ($1.7) million for Q4 2016. ChromaDex defines Adjusted EBITDA as net income (loss) adjusted for income tax, interest, depreciation, amortization and non-cash stock compensation costs. The Basic and Diluted Adjusted EBITDA per share for Q4 2017 was ($0.10) versus ($0.05) for Q4 2016.

We also ended the fourth quarter of 2017 with a solid balance sheet with quarter-end cash of $45.4 million.

“We continue to see validation from the research community, as evidence builds through peer-reviewed publications,” said Frank Jaksch, Jr., CEO and co-founder of ChromaDex. “Our undisputed leadership in NAD research will be the foundation of continued growth for TRU NIAGEN.”

Rob Fried, President and Chief Operating Officer commented: “It has been less than a year since we made the strategic decision to focus on TRU NIAGEN and NAD. We are very pleased with the increase in gross margin which reflects the growing value of the TRU NIAGEN brand. Our strategy is thus far playing out ahead of plan.”

Results of operations for the year ended Dec. 30, 2017

For full year 2017, net revenues were $21.2 million from continuing operations, down 2% compared to $21.7 million from continuing operations for full year 2016 as the Company shifted to an integrated global consumer product nutraceutical company.

Gross profit improved in the full year 2017 to 49.4% as compared to 48.0% for the same period in 2016. We experienced slightly better margins due to the positive impact of TRU NIAGEN consumer product.

For full year 2017, operating expenses from continuing operations were $26.9 million, compared to $13.3 million from continuing operations for full year 2016 as we invested in marketing expenditures to build out the TRU NIAGEN brand. The increase in operating expenses was also due to legal costs associated with ongoing litigation and higher stock-based compensation expense.

The net loss attributable to common stockholders for full year 2017 was $11.4 million or ($0.26) per share as compared to a net loss of $2.9 million or ($0.08) per share for full year 2016.

Adjusted EBITDA a non-GAAP measure, was ($5.9) million for 2017, compared to adjusted EBITDA of ($0.9) million for 2016. The Basic and Diluted Adjusted EBITDA per share for 2017 was ($0.13) versus ($0.03) for 2016.

Outlook

For 2018, the Company expects to show significant growth in sales driven by our U.S. ecommerce and Watsons business and the launch of TRU NIAGEN in new international markets. We expect the growth to be skewed toward the second half of the year. We will continue to invest in marketing expenditures to build out the TRU NIAGEN brand, infrastructure, and new capabilities to support growth.

Investor Conference Call

ChromaDex management will host an investor conference call to discuss the year end results and provide a general business update on Thurs., March 8, at 4:30pm ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

U.S. Toll-Free Number:(866) 327-8118
International Dial-In Number: (678) 509-7526
Conference ID:9787028
Webcast link:https://edge.media-server.com/m6/p/8kcvfrii


The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.

The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.

About Non-GAAP Financial Measures

ChromaDex’s non-GAAP financial measures exclude interest, tax, depreciation, amortization and share-based compensation. ChromaDex used these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. These non-GAAP measures should not be viewed in isolation from or as a substitute for ChromaDex’s financial results in accordance with GAAP. A reconciliation of GAAP to non-GAAP measures is attached to this press release.

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com.

Important Note on Forward Looking Statements and 2017 Financial Results:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include statements regarding the Company’s fourth quarter and full year 2017 financial results, continued growth in revenue and gross profits and continued validation of our science. The financial information included herein for the fourth quarter and full year 2017 are preliminary, unaudited results and may change materially, including as a result of the finalization of financial statements for the Company’s fourth quarter and full year ended December 30, 2017, completion of the Company’s audit by the Company’s independent registered public accounting firm and other factors and adjustments related to the Company’s financial reporting process. Other risks that contribute to the uncertain nature of the forward-looking statements are reported in our most recent Forms 10-Q and 10-K as filed with the SEC. There can be no assurance that our final results for the year will not differ from these estimates and that such changes will not be material; accordingly, these statements should not be viewed or relied upon as a substitute for complete audited financial statements to be prepared in accordance with GAAP (Generally Accepted Accounting Principles) or as a measure of our actual performance. The Company plans to file its 2017 Annual Report on Form 10-K with the SEC on or around March 15, 2018. The 2017 Annual Report on Form 10-K will include audited financial statements for the year ended December 30, 2017.

ChromaDex Investor Relations Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com

ChromaDex Public Relations Contact:

Breah Ostendorf, Director of Marketing

949-537-4103

breaho@chromadex.com



ChromaDex Corporation and Subsidiaries
Consolidated Statements of Operations
Three Months Ended December 30, 2017 and December 31, 2016
Q4 2017Q4 2016
Sales, net$ 7,530,836 $ 4,452,783
Cost of sales 3,695,837 2,442,714
Gross profit 3,834,999 2,010,069
Operating expenses:
Sales and marketing 2,401,046 368,200
Research and development 1,452,668 534,171
General and administrative 8,759,068 3,279,624
Operating expenses 12,612,782 4,181,995
Operating loss (8,777,783) (2,171,926)
Nonoperating income (expense):
Interest expense, net (44,033) (18,360)
Nonoperating expenses (44,033) (18,360)
Loss before income taxes (8,821,816) (2,190,286)
Provision for income taxes - 3,500
Loss from continuing operations (8,821,816) (2,186,786)
Income from discontinued operations - 40,033
Net loss$ (8,821,816)$ (2,146,753)
Basic and diluted earnings (loss) per common share:
Loss from continuing operations$ (0.17)$ (0.06)
Earnings from discontinued operations$ - $ 0.00
Basic and diluted loss per common share$ (0.17)$ (0.06)
Basic and diluted weighted average common shares outstanding 51,178,664 37,904,534


ChromaDex Corporation and Subsidiaries
Consolidated Statements of Operations
Years Ended December 30, 2017 and December 31, 2016
20172016
Sales, net$ 21,201,482 $ 21,664,648
Cost of sales 10,724,177 11,274,114
Gross profit 10,477,305 10,390,534
Operating expenses:
Sales and marketing 4,459,224 1,558,213
Research and development 4,007,381 2,522,768
General and administrative 17,641,889 9,214,763
Other 745,773 -
Operating expenses 26,854,267 13,295,744
Operating loss (16,376,962) (2,905,210)
Nonoperating income (expense):
Interest expense, net (152,784) (333,286)
Loss on debt extinguishment - (313,099)
Nonoperating expenses (152,784) (646,385)
Loss from continuing operations (16,529,746) (3,551,595)
Income (loss) from discontinued operations (315,140) 623,410
Gain on sale of discontinued operations 5,467,268 -
Income from discontinued operations, net 5,152,128 623,410
Net loss$ (11,377,618)$ (2,928,185)
Basic and diluted earnings (loss) per common share:
Loss from continuing operations$ (0.37)$ (0.10)
Earnings from discontinued operations$ 0.11 $ 0.02
Basic and diluted loss per common share$ (0.26)$ (0.08)
Basic and diluted weighted average common shares outstanding 44,598,879 37,294,321


Consolidated Statements of Operations, Unaudited Effects of Charges associated with Interest, Tax, Depreciation, Consolidated Statements of Operations, Adjusted EBITDA
(US GAAP) Amortization and Share-based Compensation Expense Excluding Interest, Tax, Depreciation, Amortization and
Share-based Compensation (Non-GAAP Presentation)
Three Months Ended December 30, 2017 and December 31, 2016 Three Months Ended December 30, 2017 and December 31, 2016 Three Months Ended December 30, 2017 and December 31, 2016
Q4 2017Q4 2016 Q4 2017Q4 2016 Q4 2017Q4 2016
Sales, net$ 7,530,836 $ 4,452,783 Sales, net$ - $ - Sales, net$ 7,530,836 $ 4,452,783
Cost of sales 3,695,837 2,442,714 Cost of sales (58,546) (18,405) Cost of sales 3,637,291 2,424,309
Gross profit 3,834,999 2,010,069 Gross profit 58,546 18,405 Gross profit 3,893,545 2,028,474
Operating expenses: Operating expenses: Operating expenses:
Sales and marketing 2,401,046 368,200 Sales and marketing (1,857) - Sales and marketing 2,399,189 368,200
Research and development 1,452,668 534,171 Research and development (41,654) (10,494) Research and development 1,411,014 523,677
General and administrative 8,759,068 3,279,624 General and administrative (3,464,320) (294,518) General and administrative 5,294,748 2,985,106
Operating expenses 12,612,782 4,181,995 Operating expenses (3,507,831) (305,012) Operating expenses 9,104,951 3,876,983
Operating loss (8,777,783) (2,171,926) Operating income 3,566,377 323,417 Operating loss (5,211,406) (1,848,509)
Nonoperating income (expense): Nonoperating income (expense): Nonoperating income (expense):
Interest expense, net (44,033) (18,360) Interest expense, net 44,033 18,360 Interest expense, net - -
Nonoperating expenses (44,033) (18,360) Nonoperating income 44,033 18,360 Nonoperating expenses - -
Loss before income taxes (8,821,816) (2,190,286) Income before income taxes 3,610,410 341,777 Loss before income taxes (5,211,406) (1,848,509)
Provision for income taxes - 3,500 Provision for income taxes - (3,500) Provision for income taxes - -
Loss from continuing operations (8,821,816) (2,186,786) Income from continuing operations 3,610,410 338,277 Loss from continuing operations (5,211,406) (1,848,509)
Income from discontinued operations - 40,033 Income from discontinued operations - 70,352 Income from discontinued operations - 110,385
Net loss$ (8,821,816)$ (2,146,753) Effects of adjusted EBITDA$ 3,610,410 $ 408,629 Adjusted EBITDA$ (5,211,406)$ (1,738,124)
Basic and diluted earnings (loss) per common share: Effects of adjusted EBITDA per common share: Basic and diluted adjusted EBITDA per common share:
Loss from continuing operations$ (0.17)$ (0.06) From continuing operations$ 0.07 $ 0.01 From continuing operations$ (0.10)$ (0.05)
Earnings from discontinued operations$ - $ 0.00 From discontinued operations$ - $ 0.00 From discontinued operations$ - $ 0.00
Basic and diluted loss per common share$ (0.17)$ (0.06) Effects of adjusted EBITDA per common share$ 0.07 $ 0.01 Basic and diluted adjusted EBITDA per common share$ (0.10)$ (0.05)
Weighted average common shares outstanding Weighted average common shares outstanding Weighted average common shares outstanding
Basic and diluted 51,178,664 37,904,534 Basic and diluted 51,178,664 37,904,534 Basic and diluted 51,178,664 37,904,534


Consolidated Statements of Operations Effects of Charges associated with Interest, Tax, Depreciation, Consolidated Statements of Operations, Adjusted EBITDA
(US GAAP) Amortization and Share-based Compensation Expense Excluding Interest, Tax, Depreciation, Amortization and
Share-based Compensation (Non-GAAP Presentation)
Years Ended December 30, 2017 and December 31, 2016 Years Ended December 30, 2017 and December 31, 2016 Years Ended December 30, 2017 and December 31, 2016
20172016 20172016 20172016
Sales, net$ 21,201,482 $ 21,664,648 Sales, net$ - $ - Sales, net$ 21,201,482 $ 21,664,648
Cost of sales 10,724,177 11,274,114 Cost of sales (178,109) (42,589) Cost of sales 10,546,068 11,231,525
Gross profit 10,477,305 10,390,534 Gross profit 178,109 42,589 Gross profit 10,655,414 10,433,123
Operating expenses: Operating expenses: Operating expenses:
Sales and marketing 4,459,224 1,558,213 Sales and marketing (2,381) - Sales and marketing 4,456,843 1,558,213
Research and development 4,007,381 2,522,768 Research and development (132,285) (10,493) Research and development 3,875,096 2,512,275
General and administrative 17,641,889 9,214,763 General and administrative (4,838,865) (1,305,505) General and administrative 12,803,024 7,909,258
Other 745,773 - Other - - Other 745,773 -
Operating expenses 26,854,267 13,295,744 Operating expenses (4,973,531) (1,315,998) Operating expenses 21,880,736 11,979,746
Operating loss (16,376,962) (2,905,210) Operating income 5,151,640 1,358,587 Operating loss (11,225,322) (1,546,623)
Nonoperating income (expense): Nonoperating income (expense): Nonoperating income (expense):
Interest expense, net (152,784) (333,286) Interest expense, net 152,784 333,286 Interest expense, net - -
Loss on debt extinguishment - (313,099) Loss on debt extinguishment - - Loss on debt extinguishment - (313,099)
Nonoperating expenses (152,784) (646,385) Nonoperating income 152,784 333,286 Nonoperating expenses - (313,099)
Loss from continuing operations (16,529,746) (3,551,595) Loss from continuing operations 5,304,424 1,691,873 Loss from continuing operations (11,225,322) (1,859,722)
Income (loss) from discontinued operations (315,140) 623,410 Income from discontinued operations 193,889 291,121 Income (loss) from discontinued operations (121,251) 914,531
Gain on sale of discontinued operations 5,467,268 - Gain on sale of discontinued operations - - Gain on sale of discontinued operations 5,467,268 -
Income from discontinued operations, net 5,152,128 623,410 Income from discontinued operations, net 193,889 291,121 Income from discontinued operations, net 5,346,017 914,531
Net loss$ (11,377,618)$ (2,928,185) Effects of adjusted EBITDA$ 5,498,313 $ 1,982,994 Adjusted EBITDA$ (5,879,305)$ (945,191)
Basic and diluted earnings (loss) per common share: Effects of adjusted EBITDA per common share: Basic and diluted adjusted EBITDA per common share:
Loss from continuing operations$ (0.37)$ (0.10) From continuing operations$ 0.12 $ 0.05 From continuing operations$ (0.25)$ (0.05)
Earnings from discontinued operations$ 0.11 $ 0.02 From discontinued operations$ 0.00 $ 0.00 From discontinued operations$ 0.12 $ 0.02
Basic and diluted loss per common share$ (0.26)$ (0.08) Effects of adjusted EBITDA per common share$ 0.12 $ 0.05 Basic and diluted adjusted EBITDA per common share$ (0.13)$ (0.03)
Weighted average common shares outstanding Weighted average common shares outstanding Weighted average common shares outstanding
Basic and diluted 44,598,879 37,294,321 Basic and diluted 44,598,879 37,294,321 Basic and diluted 44,598,879 37,294,321

Source:ChromaDex Corporation